- 1Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung, Taiwan
- 2Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan
- 3Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
- 4Department of Electrical Engineering, Changhua National University of Education, Changhua, Taiwan
- 5Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan
- 6Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
Background: Parkinson’s disease (PD) is a complex neurodegenerative disease with an elusive etiology that involves the interaction between genetic, behavioral, and environmental factors. Recently, epigenetic modifications, particularly DNA methylation, have been recognized to play an important role in the onset of PD. Glycoprotein non-metastatic melanoma protein B (GPNMB), a type I transmembrane protein crucial for immune cell activation and maturation, has emerged as a potential biomarker for the risk of PD. This research aims to investigate the influence of exercise and gender on the regulation of methylation levels of GPNMB cg17274742 in individuals.
Methods: We analyze data from 2,474 participants in the Taiwan Biobank, collected from 2008 and 2016. Methylation levels at the GPNMB cg17274742 CpG site were measured using Illumina Infinium MethylationEPIC beads. After excluding individuals with incomplete data or missing information on possible risk factors, our final analysis included 1,442 participants. We used multiple linear regression models to assess the association between sex and exercise with adjusted levels of GPNMB cg17274742 for age, BMI, smoking, drinking, coffee consumption, serum uric acid levels, and hypertension.
Results: Our results demonstrated that exercise significantly influenced the methylation levels of GPNMB cg17274742 in males (β = −0.00242; p = 0.0026), but not in females (β = −0.00002362; p = 0.9785). Furthermore, male participants who exercised showed significantly lower levels of methylation compared to the reference groups of the female and non-exercising reference groups (β = −0.00357; p = 0.0079). The effect of the interaction between gender and exercise on the methylation of GPNMB cg17274742 was statistically significant (p = 0.0078).
Conclusion: This study suggests that gender and exercise can modulate GPNMB cg17274742, with hypomethylation observed in exercise men. More research is needed to understand the underlying mechanisms and implications of these epigenetic changes in the context of risk and prevention strategies.
Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein within Lewy bodies (Alam and Schmidt, 2002). PD manifests severe motor and non-motor symptoms that significantly affect the quality of life of patients and caregivers. In particular, less than 10% of cases of PD can be attributed to identified genetic causes (Farrer, 2006). The etiology of idiopathic Parkinson’s disease remains largely enigmatic; however, it is postulated that a combination of genetic, behavioral, and environmental factors contribute to its development (Blauwendraat et al., 2020).
Recently, a growing body of evidence has suggested that epigenetic modifications, particularly DNA methylation, may play a crucial role in the development and progression of PD and could play a role in pathogenesis including α-synuclein misfolding and aggregation, mitochondrial dysfunction, impaired protein clearance, neuroinflammation, and oxidative stress (Pieper et al., 2008; Masliah et al., 2013; Coupland et al., 2014; Su et al., 2015; Eryilmaz et al., 2017; Jankovic and Tan, 2020; Kia et al., 2021). DNA methylation, a biochemical modification that occurs predominantly at cytosine residues in CpG dinucleotides, can influence gene expression and contribute to the complex regulation of cellular processes (Gius et al., 2004). As aging progresses, the accumulation of errors in the epigenetic machinery increases the risk of age-related pathologies, such as brain deterioration and neurodegeneration (Salameh et al., 2020). Aberrant DNA methylation has been implicated in the dysregulation of various molecular pathways associated with PD, highlighting the importance of further investigating the role of epigenetics in the context of the pathogenesis of PD (Renani et al., 2019; Kia et al., 2021).
Glycoprotein non-metastatic melanoma protein B (GPNMB) is a type I transmembrane protein that plays a key role in immune cell maturation and activation. It has been closely associated with PD as a potential risk biomarker and in modulating neuroinflammation, a hallmark of the pathogenesis of PD (Jankovic and Tan, 2020; Saade et al., 2021; Diaz-Ortiz et al., 2022; Kaiser et al., 2023). Recent studies have shown an increase in GPNMB expression within the substantia nigra of PD patients, suggesting a risk factor through its interaction with alpha-synuclein (Moloney et al., 2018; Diaz-Ortiz et al., 2022). Recent evidence on the causality and heterogeneity of PD suggests that GPNMB is the main causal protein in the high-throughput proteomic analysis of cerebrospinal fluid (Kaiser et al., 2023). Interestingly, overexpression of GPNMB in animal models has been shown to reduce dopaminergic neuron degeneration and exert an anti-neuroinflammatory effect (Neal et al., 2018; Budge et al., 2020). Genome-wide association studies (GWAS) have also discovered single nucleotide polymorphisms (SNPs) within the GPNMB gene, which can increase the risk of PD and could be regulated by DNA methylation. Specifically, the CpG site, located in the exon region of the GPNMB gene on chromosome 7, is associated with the methylation status of the GPNMB gene (International Parkinson’s Disease Genomics Consortium (IPDGC), and Wellcome Trust Case Control Consortium 2 (WTCCC2), 2011; Nalls et al., 2014; Kia et al., 2021).
The prevalence of Parkinson’s disease varies significantly by sex, with a higher incidence observed in men than in women. This gender difference can be attributed to hormonal, genetic, and lifestyle factors (Picillo et al., 2017; Russillo et al., 2022). Several lifestyle and behavioral choices are associated with gender differences (Bellou et al., 2016; Cerri et al., 2019), and among lifestyle factors, exercise is one of the well-studied factors believed to alter DNA methylation (Daniele et al., 2018; Ferioli et al., 2019; Xu et al., 2021). Exercise can also mitigate the progression of PD, with neuroinflammatory modulation suggested as a key mechanism (Chen et al., 2005; Crotty and Schwarzschild, 2020; Xu et al., 2021; Sujkowski et al., 2022). However, complex epigenetic changes related to exercise and different sexes in PD are not fully understood.
Currently, no studies have examined the influence of sex and exercise on GPNMB expression and DNA methylation. Given that both epigenetic alterations and lifestyle factors can affect GPNMB expression and contribute to the pathogenesis of PD, this research could provide valuable information on the progression of the disease and possible interventions. Using DNA methylation data, precision public health can facilitate personalized prevention for people at risk of developing Parkinson’s disease, such as providing specific physical activity guidelines based on the individual’s unique methylation profile. Therefore, a comprehensive assessment of the impact of gender and exercise on GPNMB expression and DNA methylation status in PD could have significant implications for precision public health strategies in PD.
Materials and methods
Data source and participants
Data for this study were sourced from Taiwan Biobank (TWB), an ongoing prospective cohort study that includes more than 150,000 participants. The TWB contains demographic and whole genome sequencing data from Taiwanese (99% Han Chinese) between 20 and 70 years of age who do not have a cancer diagnosis, with lifestyle information obtained through individual interviews (Chen et al., 2016; Wei et al., 2021).
Anthropometric and biochemical data was collected from the medical centers that enroll subjects. Initially, 2,474 participants were enrolled in this study. After the exclusion of patients with incomplete data (N = 1,032), the final sample for analysis consisted of 1,442 subjects.
This study was approved by the Institutional Review Board of the Chung Shan Medical University Hospital (CS1-20009).
DNA methylation
Methylation profiles were analyzed with the Infinium MethylationEPIC BeadChip Kit (Illumina Inc., San Diego, CA, United States) (Shen et al., 2007; Irizarry et al., 2008; du et al., 2010), which targets more than 850,000 CpG sites. Epigenetic data was obtained from whole blood samples. Epigenetic data was extracted from whole blood. We adjust the cell-type composition using the Reference-Free Adjustment for Cell-Type Composition (ReFACTor) method (Chen et al., 2016). Methylation levels were quantified using a beta value (0–1) to present hypo/hypermethylation. Beta value of the CpG site within the exon region of the GPNMB gene.
Outcome definition and covariates
The beta value of GPNMB cg17274742 for each participant. Body mass index (BMI) (kg/m2) was calculated as body weight (kilogram) divided by body height (meter) squared. The BMI classifications were the following: underweight (0 to 18.5), normal (18.5 to 24), overweight (), and obese (more than 27). For this study, people who exercised for more than 30 min at least three times a week were considered to have regular exercise habits. The waist-hip ratio (WHR) is derived by dividing the waist circumference by the hip circumference. Current drinkers were classified as individuals who consumed more than 150 mL/week in the previous 6 months, while former drinkers had abstained for at least 6 months. Current smokers were identified as individuals who smoked continuously within the last 6 months, and former smokers had resisted smoking for at least 6 months. Coffee consumption was classified into ‘no / yes’ groups. A positive history of hypertension was determined in the self-report of a physician’s diagnosis. Taiwan Biobank has commissioned the Linkou Branch of Chang Gung Memorial Hospital to supervise blood and urine analyzes. Within the scope of serological assessments, particular emphasis is placed on the quantification of uric acid, with a reference threshold established at <7 mg/dL.
Statistical analysis
To investigate the association between methylation in GPNMB cg17274742 and sex and exercise status, multiple linear regression was used after adjusting for age, BMI, smoking status, alcohol consumption, coffee intake, serum uric acid level, and hypertension. The interaction between sex and exercise was also considered in the model. Statistical significance was established with a value of p <0.05 in a two-tailed test. Differences were evaluated using the t-test for continuous variables and the chi-square test for categorical variables. All analysis procedures were performed using the SAS 9.4 software version (SAS Institute Inc., Cary, NC, United States).
Results
The analysis included a total of 1,442 subjects (men = 690, women = 752). The average age of the participants was similar between sexes (48.73 ± 0.39 for women, 49.66 ± 0.43 for men, p-value = 0.1121) (Table 1). The level of methylation of GPNMB cg17274742 (beta value) did not show significant differences between men and women (0.9480 ± 0.000401 in men, 0.9487 ± 0.000428 in women, p-value = 0.2257). Men exhibited a higher proportion of regular exercise (47.1% in men, 40.7% in women, p = 0.0142), higher BMI (61.6% in men, 37.3% in women, p < 0.0001), higher prevalence of smoking (42.7% in men, 6.4% in women, p < 0.0001), alcohol consumption (17.8% in men, 2.3% in women, p < 0.0001), history of hypertension (17% in men, 8.1% in women, p < 0.0001), and higher serum uric acid levels (6.34 mg/dL in men, 4.76 mg/dL in women, p < 0.0001). Coffee consumption was comparable between sexes. The WHR for women is manifested as 0.8411 ± 0.003, while for men, it registers at 0.8931 ± 0.002.
The regression model revealed that being male was associated with a significantly lower level of GPNMB cg17274742 than being female (β = −0.00252; p-value = 0.0417) after adjusting for possible confounders (Table 2). Furthermore, patients with hypertension showed a higher beta value, indicative of hypermethylation. Regular exercise was not associated with the level of methylation (β = −0.00108; p-value = 0.0681).
A significant interaction was observed between sex and exercise on the methylation of GPNMB cg17274742 (p-value = 0.0078). Stratified analysis by sex (Table 3) revealed that exercise was associated with GPNMB cg17274742 only in men (β = −0.00242; p-value = 0.0026) and not in women (β = −0.00002362; p-value = 0.9785). When stratified by exercise, no significant association was found for either sex group (Table 4). When considering sex and exercise together, men who exercised regularly exhibited significantly lower levels of GPNMB cg17274742 compared to women who did not exercise regular exercise (β = −0.00357; p-value = 0.0079) (Table 5).
Discussion
Using data from a large prospective cohort, we discerned a sex-specific association between exercise and methylation status. Our findings suggest that men who exercise regularly have a lower level of methylation of cg17274742, which can result in increased expression of GPNMB. Furthermore, we can discern a tangible impact of exercise on methylation patterns at the cg17274742 locus, particularly within the male cohort. Men who exercise are observed to experience a significant reduction in methylation at this genomic site. When these data are juxtaposed against the corresponding female cohort, a stark contrast emerges. Within the exercise-engaged population, males show a more pronounced decrease in methylation relative to females. These findings not only reveal a complex interplay between physical exercise and DNA methylation, but also underscore the need to consider gender-specific variations in the field of epigenetic research. This is the first study to find a relationship between different sexes and exercise-associated methylation changes, suggesting that a lifestyle change, particularly a routine exercise habit in men, could increase the expression of GPNMB, which is highly correlated with Parkinson’s disease and the anti-inflammatory reaction.
GPNMB is a protein that is found in cell membranes of various tissues, including the nervous system, skin, and bone (Lazaratos et al., 2022). Previous studies have noted the importance of different biological processes and functions of GPNMB, including cell differentiation and development, inflammation and immune response, progression, and neurodegeneration deterioration (Zhang et al., 2017; Neal et al., 2018; Budge et al., 2020; Saade et al., 2021; Diaz-Ortiz et al., 2022; Lazaratos et al., 2022). GPNMB can have neuroprotective effects in mitigating the effects of harmful protein aggregates, a common feature in many neurodegenerative diseases (Tanaka et al., 2012; Budge et al., 2018; Zhu et al., 2022). Gpnmb levels are a reliable indicator of the severity of the disease in various medical conditions. When Gpnmb is up-regulated, it is commonly associated with infiltration of antigen-presenting cells into the affected tissue (Maric et al., 2013; Suda et al., 2022). Initially, significant up-regulation is often interpreted as disease-related and harmful. However, it is essential to consider that up-regulation of Gpnmb may result from macrophages that exert anti-inflammatory and immune-balancing effects, possibly through interactions with T cells. Cancer cells may take advantage of this immune-dampening property of Gpnmb to enhance their progression. The role of Gpnmb in different diseases, especially neurodegenerative diseases, becomes complex, particularly due to potential variations in its function when bound to cells or present in a soluble form (Tanaka et al., 2012; Neal et al., 2018; Xie et al., 2019; Saade et al., 2021; Zhu et al., 2022).
Recent studies highlight the importance and benefits of involving diverse and multi-ethnic populations in genetic studies (Popejoy and Fullerton, 2016; Graham et al., 2021) including a more accurate representation of the risks of genetically associated diseases in different populations (Sirugo et al., 2019). To our knowledge, most published genome-wide association studies (GWAS) and methylomic investigations involving GPNMB variants were conducted predominantly with Caucasian populations (Nalls et al., 2014; Chang et al., 2017; Murthy et al., 2017; Iwaki et al., 2019; Prasad and Jho, 2019; Langmyhr et al., 2021). Our study used information from the Taiwan Biobank (TWB), the largest biobank in East Asia, known for its high-coverage whole genome sequencing and DNA methylation data in a Han Chinese population (Wei et al., 2021).
A recent comprehensive strategy aims to colocalize the expression quantitative trait loci (eQTL) and GWAS signals in PD using an updated PD GWAS dataset. The methylation study identified cg17274742 in the GPNMB gene, which has implications for Coloc expression, which evaluates shared causal variants between eQTL and GWAS signals. Methylation has an impact on gene expression, and specifically cg17274742 in GPNMB influences not only expression but also the splicing function at the GPNMB (gene level)/ NUPL2 (splicing) locus through strong protein–protein interactions evidence that connects to mendelian or sporadic risk genes (Kia et al., 2021). PD-associated variants exert their influence on GPNMB through this methylation site, uncovering molecular insights into the mechanisms of PD and underscoring the importance of genetic and epigenetic factors.
We observed a predominant hypomethylation of cg17274742 in men, which could lead to an increase in GPNMB expression. After adjusting for age in the epidemiological study, the prevalence of PD in men is approximately 1.4 times that of women (Dorsey et al., 2018) although a 2014 meta-analysis suggests that this difference is evident only in the age group (Pringsheim et al., 2014). The sex differences in GPNMB cg17274742 observed in our study could partially explain this prevalence disparity in PD. Hormonal variances, especially estrogen levels, can contribute to risk and progression, given the neuroprotective effects demonstrated in animal models (Russillo et al., 2022). The intricate interplay of sex hormones, such as estrogens, manifests itself as a modulatory influence on humoral immunity, effectively improving its response. In contrast, androgens, progesterone, and glucocorticoids exhibit inherent immunosuppressive properties that contribute to the regulation and fine-tuning of the immune system. Of particular importance is the heterogeneity of sex steroids, which encompass estrogens, progesterone, and testosterone, which exhibit notable differences between genders and undergo dynamic changes in various reproductive phases. These complex hormonal variations exert a substantial influence on the intricate details of neural function, prompting a critical exploration of their roles in neurological pathophysiology (Bouman et al., 2005). GPNMB protein was also found to be regulated by sex hormones or modulated in a specific sex manner in deep immunophenotyping animal model studies (Tsui et al., 2012; Houser et al., 2022). Recent research has also identified specific sex changes in DNA methylation in brain tissue (Kochmanski et al., 2022).
Furthermore, our findings indicate that hypertension is associated with hypermethylation of cg17274742, which could reduce the expression of GPNMB and therefore possibly lower the risk of PD (Murthy et al., 2017; Diaz-Ortiz et al., 2022). However, the existing literature presents contradictory evidence linking hypertension and the diagnosis of PD, and different effects of hypertension have been reported in Caucasian versus Asian populations (McCann et al., 1998; Paganini-Hill, 2001; Qiu et al., 2011; Hou et al., 2018; Chen et al., 2019; Ng et al., 2021). Additionally, certain antihypertensive medications can influence the risk of PD (Lee et al., 2014; Cai et al., 2019; Simmering et al., 2021; Jo et al., 2022; Lin et al., 2022; Simmering et al., 2022).
Regular exercise is widely recognized to exert a protective influence against PD through mechanisms such as neuroplasticity, angiogenesis, and modulation of oxidative damage and neuroinflammation (Ascherio and Schwarzschild, 2016; Jang et al., 2017; Palasz et al., 2019; Mahalakshmi et al., 2020; Ruiz-González et al., 2021; Mazo et al., 2022). Increasing evidence suggests that exercise can alter brain function and structure, slowing the progression of motor and non-motor symptoms of PD (Reynolds et al., 2016; Schenkman et al., 2018; van der Kolk et al., 2019; Johansson et al., 2022; Tsukita et al., 2022). Exercise can also produce gender-specific effects on gene regulation and expression through epigenetic modifications and hormonal changes (Landen et al., 2019; Wu et al., 2020). Both the innate and adaptive immune systems involve essential cellular components that possess receptors for sex hormones, enabling them to respond to hormonal signals. This intriguing observation suggests that the impact of exercise on the immune system could differ between men and women, highlighting the potential role of sex-dependent factors in mediating immune responses during physical activity (Kadel and Kovats, 2018; Fuentes and Silveyra, 2019; Becerra-Diaz et al., 2020). In a similar vein, the female reproductive cycle can influence changes in the expression of inflammatory genes induced by exercise in various circumstances (Northoff et al., 2008). In addition, there is an ongoing debate about the contrasting effects of different types of exercise on immune responses and related outcomes between men and women (Soligard et al., 2017; Barrett et al., 2018; Drew et al., 2018; Zhou et al., 2018). Furthermore, a large-scale epigenome-wide association meta-analysis suggested that genes with differences in methylation between sexes are also present in human skeletal muscle (Landen et al., 2021).
The first limitations of our research include the focus on carriers of the GPNMB variant, rather than individuals with a clinically confirmed diagnosis of Parkinson’s disease. However, the potential influence of methylation alterations on gene expression, compounded by environmental and lifestyle variables, underscores the importance of precision public health in our investigative approach. To capitalize on this concept, our study aims to elucidate the lifestyle determinants that affect gene carriers during the incipient stages of the disease. Through these insights, we anticipate the development of suitable interventions that can postpone the onset of the disease. The second source of uncertainty is that according to the Taiwan Human Biobank, inquiries related to alcohol consumption only address drinking habits and do not include questions pertaining to the quantification of alcohol intake, and only address the frequency of smoking, without encompassing questions related to the total volume of cigarette consumption. The other constraint of our study lies in the inability to fully account for all possible confounders, such as diet, lifestyle, and environmental exposure. However, we adjusted for factors such as age, BMI, smoking, drinking, coffee consumption, serum uric acid levels, and hypertension, which are widely recognized as potential risk or protective factors based on extensive epidemiological studies. Although our research offers valuable information on the relationship between exercise and DNA methylation between sexes, the findings should be interpreted with caution due to the limitations of the study. Future experimental studies could potentially confirm our findings using animal models, further elucidating the causal relationship between exercise and DNA methylation of the GPNMB gene in different sexes.
Ultimately, our results provide epigenetic insight into the sex and lifestyle factors associated with GPNMB expression, which served as a potential biomarker and therapeutic target for PD. DNA methylation presents a promising avenue for the application of precision public health in the treatment of PD, including personalized diet recommendations and exercise programs for different sexes based on an individual methylation profile. More research is needed to fully understand the intricate relationships between lifestyle factors, DNA methylation, and the progression of PD.
Data availability statement
The data analyzed in this study is subject to the following licenses/restrictions: Data supporting the findings of this study are available from the Taiwan Biobank, but restrictions apply to the availability of these data, which were used under license for the current study and are not publicly available. However, the data are available from the authors upon reasonable request and with permission of Taiwan Biobank. Requests to access these datasets should be directed to Y-PL, bGlhd3lwQGNzbXUuZWR1LnR3.
Ethics statement
The studies involving humans were approved by the Institutional Review Board of the Chung Shan Medical University Hospital (CS1-20009). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
Y-CC, S-LW, and Y-PL: conceptualization. C-HH and J-HZ: data curation and formal analysis. ON, Y-CC, and Y-PL: methodology. S-LW and Y-PL: supervision. Y-CC: writing – original draft. Y-CC and Y-CL: writing-review & editing. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by the Ministry of Science and Technology (MOST 109-2121-M-040-002; 109-2811-M-040-500; 110-2811-M-040-001; 110- 2121-M-040-002; 111-2811-M-040-001; 111-2121-M-040-002; 111-2811-M- 040-001).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Alam, M., and Schmidt, W. J. (2002). Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136, 317–324. doi: 10.1016/S0166-4328(02)00180-8
Ascherio, A., and Schwarzschild, M. A. (2016). The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 15, 1257–1272. doi: 10.1016/S1474-4422(16)30230-7
Barrett, B., Hayney, M. S., Muller, D., Rakel, D., Brown, R., Zgierska, A. E., et al. (2018). Meditation or exercise for preventing acute respiratory infection (MEPARI-2): a randomized controlled trial. PLoS One 13:e0197778. doi: 10.1371/journal.pone.0197778
Becerra-Diaz, M., Song, M., and Heller, N. (2020). Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung. Front. Immunol. 11:1698. doi: 10.3389/fimmu.2020.01698
Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E., and Ioannidis, J. P. (2016). Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. Parkinsonism Relat. Disord. 23, 1–9. doi: 10.1016/j.parkreldis.2015.12.008
Blauwendraat, C., Nalls, M. A., and Singleton, A. B. (2020). The genetic architecture of Parkinson’s disease. Lancet Neurol. 19, 170–178. doi: 10.1016/S1474-4422(19)30287-X
Bouman, A., Heineman, M. J., and Faas, M. M. (2005). Sex hormones and the immune response in humans. Hum. Reprod. Update 11, 411–423. doi: 10.1093/humupd/dmi008
Budge, K. M., Neal, M. L., Richardson, J. R., and Safadi, F. F. (2018). Glycoprotein NMB: an emerging role in neurodegenerative disease. Mol. Neurobiol. 55, 5167–5176. doi: 10.1007/s12035-017-0707-z
Budge, K. M., Neal, M. L., Richardson, J. R., and Safadi, F. F. (2020). Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration. Mol. Neurobiol. 57, 2920–2933. doi: 10.1007/s12035-020-01921-6
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., et al. (2019). Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases. J. Clin. Investig. 129, 4539–4549. doi: 10.1172/JCI129987
Cerri, S., Mus, L., and Blandini, F. (2019). Parkinson’s disease in women and men: What’s the difference? J. Parkinsons Dis. 9, 501–515. doi: 10.3233/JPD-191683
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., et al. (2017). A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat. Genet. 49, 1511–1516. doi: 10.1038/ng.3955
Chen, C. H., Yang, J. H., Chiang, C. W. K., Hsiung, C. N., Wu, P. E., Chang, L. C., et al. (2016). Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan biobank project. Hum. Mol. Genet. 25, 5321–5331. doi: 10.1093/hmg/ddw346
Chen, H., Zhang, S. M., Schwarzschild, M. A., Hernán, M. A., and Ascherio, A. (2005). Physical activity and the risk of Parkinson disease. Neurology 64, 664–669. doi: 10.1212/01.WNL.0000151960.28687.93
Chen, J., Zhang, C., Wu, Y., and Zhang, D. (2019). Association between hypertension and the risk of Parkinson’s disease: a meta-analysis of analytical studies. Neuroepidemiology 52, 181–192. doi: 10.1159/000496977
Coupland, K. G., Mellick, G. D., Silburn, P. A., Mather, K., Armstrong, N. J., Sachdev, P. S., et al. (2014). DNA methylation of the MAPT gene in Parkinson’s disease cohorts and modulation by vitamin E in vitro. Mov. Disord. 29, 1606–1614. doi: 10.1002/mds.25784
Crotty, G. F., and Schwarzschild, M. A. (2020). Chasing protection in Parkinson’s disease: does exercise reduce risk and progression? Front. Aging Neurosci. 12:186. doi: 10.3389/fnagi.2020.00186
Daniele, S., Costa, B., Pietrobono, D., Giacomelli, C., Iofrida, C., Trincavelli, M. L., et al. (2018). Epigenetic modifications of the <i>α</i>-Synuclein gene and Relative protein content are affected by ageing and physical exercise in blood from healthy subjects. Oxidative Med. Cell. Longev. 2018:3740345. doi: 10.1155/2018/3740345
Diaz-Ortiz, M. E., Seo, Y., Posavi, M., Carceles Cordon, M., Clark, E., Jain, N., et al. (2022). GPNMB confers risk for Parkinson’s disease through interaction with alpha-synuclein. Science 377:eabk0637. doi: 10.1126/science.abk0637
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., et al. (2018). Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 17, 939–953. doi: 10.1016/S1474-4422(18)30295-3
Drew, M., Vlahovich, N., Hughes, D., Appaneal, R., Burke, L. M., Lundy, B., et al. (2018). Prevalence of illness, poor mental health and sleep quality and low energy availability prior to the 2016 summer Olympic games. Br. J. Sports Med. 52, 47–53. doi: 10.1136/bjsports-2017-098208
du, P., Zhang, X., Huang, C. C., Jafari, N., Kibbe, W. A., Hou, L., et al. (2010). Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11:587. doi: 10.1186/1471-2105-11-587
Eryilmaz, I. E., Cecener, G., Erer, S., Egeli, U., Tunca, B., Zarifoglu, M., et al. (2017). Epigenetic approach to early-onset Parkinson’s disease: low methylation status of SNCA and PARK2 promoter regions. Neurol. Res. 39, 965–972. doi: 10.1080/01616412.2017.1368141
Farrer, M. J. (2006). Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306–318. doi: 10.1038/nrg1831
Ferioli, M., Zauli, G., Maiorano, P., Milani, D., Mirandola, P., and Neri, L. M. (2019). Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process. J. Cell. Physiol. 234, 14852–14864. doi: 10.1002/jcp.28304
Fuentes, N., and Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Adv. Protein Chem. Struct. Biol. 116, 135–170. doi: 10.1016/bs.apcsb.2019.01.001
Gius, D., Cui, H., Bradbury, C. M., Cook, J., Smart, D. K., Zhao, S., et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6, 361–371. doi: 10.1016/j.ccr.2004.08.029
Graham, S. E., Clarke, S. L., Wu, K.-H. H., Kanoni, S., Zajac, G. J. M., Ramdas, S., et al. (2021). The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679. doi: 10.1038/s41586-021-04064-3
Hou, L., Li, Q., Jiang, L., Qiu, H., Geng, C., Hong, J. S., et al. (2018). Hypertension and diagnosis of Parkinson’s disease: a meta-analysis of cohort studies. Front. Neurol. 9:162. doi: 10.3389/fneur.2018.00162
Houser, M. C., Uriarte Huarte, O., Wallings, R. L., Keating, C. E., MacPherson, K. P., Herrick, M. K., et al. (2022). Progranulin loss results in sex-dependent dysregulation of the peripheral and central immune system. Front. Immunol. 13:1056417. doi: 10.3389/fimmu.2022.1056417
International Parkinson’s Disease Genomics Consortium (IPDGC), and Wellcome Trust Case Control Consortium 2 (WTCCC2) (2011). A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet. 7:e1002142. doi: 10.1371/journal.pgen.1002142
Irizarry, R. A., Ladd-Acosta, C., Carvalho, B., Wu, H., Brandenburg, S. A., Jeddeloh, J. A., et al. (2008). Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18, 780–790. doi: 10.1101/gr.7301508
Iwaki, H., Blauwendraat, C., Leonard, H. L., Liu, G., Maple-Grødem, J., Corvol, J. C., et al. (2019). Genetic risk of Parkinson disease and progression:: an analysis of 13 longitudinal cohorts. Neurol. Genet. 5:e348. doi: 10.1212/NXG.0000000000000348
Jang, Y., Koo, J. H., Kwon, I., Kang, E. B., Um, H. S., Soya, H., et al. (2017). Neuroprotective effects of endurance exercise against neuroinflammation in MPTP-induced Parkinson’s disease mice. Brain Res. 1655, 186–193. doi: 10.1016/j.brainres.2016.10.029
Jankovic, J., and Tan, E. K. (2020). Parkinson’s disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 91, 795–808. doi: 10.1136/jnnp-2019-322338
Jo, Y., Kim, S., Ye, B. S., Lee, E., and Yu, Y. M. (2022). Protective effect of renin-angiotensin system inhibitors on Parkinson’s disease: a Nationwide cohort study. Front. Pharmacol. 13:837890. doi: 10.3389/fphar.2022.837890
Johansson, M. E., Cameron, I. G. M., van der Kolk, N. M., de Vries, N. M., Klimars, E., Toni, I., et al. (2022). Aerobic exercise alters brain function and structure in Parkinson’s disease: a randomized controlled trial. Ann. Neurol. 91, 203–216. doi: 10.1002/ana.26291
Kadel, S., and Kovats, S. (2018). Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front. Immunol. 9:1653. doi: 10.3389/fimmu.2018.01653
Kaiser, S., Zhang, L., Mollenhauer, B., Jacob, J., Longerich, S., Del-Aguila, J., et al. (2023). A proteogenomic view of Parkinson’s disease causality and heterogeneity. NPJ Parkinson’s Dis. 9:24. doi: 10.1038/s41531-023-00461-9
Kia, D. A., Zhang, D., Guelfi, S., Manzoni, C., Hubbard, L., Reynolds, R. H., et al. (2021). Identification of candidate Parkinson disease genes by integrating genome-wide association study, expression, and epigenetic data sets. JAMA Neurol. 78:464. doi: 10.1001/jamaneurol.2020.5257
Kochmanski, J., Kuhn, N. C., and Bernstein, A. I. (2022). Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2β), and NR4A2 (NURR1) in cortical neurons. NPJ Parkinson’s Dis. 8:120. doi: 10.1038/s41531-022-00355-2
Landen, S., Jacques, M., Hiam, D., Alvarez-Romero, J., Harvey, N. R., Haupt, L. M., et al. (2021). Skeletal muscle methylome and transcriptome integration reveals profound sex differences related to muscle function and substrate metabolism. Clin. Epigenetics 13:202. doi: 10.1186/s13148-021-01188-1
Landen, S., Voisin, S., Craig, J. M., McGee, S. L., Lamon, S., and Eynon, N. (2019). Genetic and epigenetic sex-specific adaptations to endurance exercise. Epigenetics 14, 523–535. doi: 10.1080/15592294.2019.1603961
Langmyhr, M., Henriksen, S. P., Cappelletti, C., van de Berg, W. D. J., Pihlstrøm, L., and Toft, M. (2021). Allele-specific expression of Parkinson’s disease susceptibility genes in human brain. Sci. Rep. 11:504. doi: 10.1038/s41598-020-79990-9
Lazaratos, A.-M., Annis, M. G., and Siegel, P. M. (2022). GPNMB: a potent inducer of immunosuppression in cancer. Oncogene 41, 4573–4590. doi: 10.1038/s41388-022-02443-2
Lee, Y.-C., Lin, C.-H., Wu, R.-M., Lin, J.-W., Chang, C.-H., and Lai, M.-S. (2014). Antihypertensive agents and risk of Parkinson’s disease: a Nationwide cohort study. PLoS One 9:e98961. doi: 10.1371/journal.pone.0098961
Lin, H. C., Tseng, Y. F., Shen, A. L., Chao, J. C., Hsu, C. Y., and Lin, H. L. (2022). Association of Angiotensin Receptor Blockers with incident Parkinson disease in patients with hypertension: a retrospective cohort study. Am. J. Med. 135, 1001–1007. doi: 10.1016/j.amjmed.2022.04.029
Mahalakshmi, B., Maurya, N., Lee, S. D., and Bharath, K. V. (2020). Possible neuroprotective mechanisms of physical exercise in neurodegeneration. Int. J. Mol. Sci. 21. doi: 10.3390/ijms21165895
Maric, G., Rose, A. A., Annis, M. G., and Siegel, P. M. (2013). Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Onco. Targets. Ther. 6, 839–852. doi: 10.2147/OTT.S44906
Masliah, E., Dumaop, W., Galasko, D., and Desplats, P. (2013). Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 8, 1030–1038. doi: 10.4161/epi.25865
Mazo, C. E., Miranda, E. R., Shadiow, J., Vesia, M., and Haus, J. M. (2022). High intensity acute aerobic exercise elicits alterations in circulating and skeletal muscle tissue expression of neuroprotective Exerkines. Brain Plast. 8, 5–18. doi: 10.3233/BPL-220137
McCann, S. J., LeCouteur, D. G., Green, A. C., Brayne, C., Johnson, A. G., Chan, D., et al. (1998). The epidemiology of Parkinson’s disease in an Australian population. Neuroepidemiology 17, 310–317. doi: 10.1159/000026185
Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O., and Hallett, P. J. (2018). The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol. Dis. 120, 1–11. doi: 10.1016/j.nbd.2018.08.013
Murthy, M. N., Blauwendraat, C., Guelfi, S., Hardy, J., Lewis, P. A., and Trabzuni, D. (2017). Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson’s disease on chromosome 7p15.3. Neurogenetics 18, 121–133. doi: 10.1007/s10048-017-0514-8
Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993. doi: 10.1038/ng.3043
Neal, M. L., Boyle, A. M., Budge, K. M., Safadi, F. F., and Richardson, J. R. (2018). The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J. Neuroinflammation 15:73. doi: 10.1186/s12974-018-1100-1
Ng, Y.-F., Ng, E., Lim, E.-W., Prakash, K. M., Tan, L. C. S., and Tan, E.-K. (2021). Case-control study of hypertension and Parkinson’s disease. NPJ Parkinson’s Dis. 7:24. doi: 10.1038/s41531-021-00202-w
Northoff, H., Symons, S., Zieker, D., Schaible, E. V., Schäfer, K., Thoma, S., et al. (2008). Gender- and menstrual phase dependent regulation of inflammatory gene expression in response to aerobic exercise. Exerc. Immunol. Rev. 14, 86–103.
Paganini-Hill, A. (2001). Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology 20, 118–124. doi: 10.1159/000054770
Palasz, E., Niewiadomski, W., Gasiorowska, A., Wysocka, A., Stepniewska, A., and Niewiadomska, G. (2019). Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson’s disease. Front. Neurol. 10:1143. doi: 10.3389/fneur.2019.01143
Picillo, M., Nicoletti, A., Fetoni, V., Garavaglia, B., Barone, P., and Pellecchia, M. T. (2017). The relevance of gender in Parkinson’s disease: a review. J. Neurol. 264, 1583–1607. doi: 10.1007/s00415-016-8384-9
Pieper, H. C., Evert, B. O., Kaut, O., Riederer, P. F., Waha, A., and Wüllner, U. (2008). Different methylation of the TNF-alpha promoter in cortex and substantia nigra: implications for selective neuronal vulnerability. Neurobiol. Dis. 32, 521–527. doi: 10.1016/j.nbd.2008.09.010
Popejoy, A. B., and Fullerton, S. M. (2016). Genomics is failing on diversity. Nature 538, 161–164. doi: 10.1038/538161a
Prasad, R., and Jho, E. H. (2019). A concise review of human brain methylome during aging and neurodegenerative diseases. BMB Rep. 52, 577–588. doi: 10.5483/BMBRep.2019.52.10.215
Pringsheim, T., Jette, N., Frolkis, A., and Steeves, T. D. (2014). The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov. Disord. 29, 1583–1590. doi: 10.1002/mds.25945
Qiu, C., Hu, G., Kivipelto, M., Laatikainen, T., Antikainen, R., Fratiglioni, L., et al. (2011). Association of Blood Pressure and Hypertension with the risk of Parkinson disease. Hypertension 57, 1094–1100. doi: 10.1161/HYPERTENSIONAHA.111.171249
Renani, P. G., Taheri, F., Rostami, D., Farahani, N., Abdolkarimi, H., Abdollahi, E., et al. (2019). Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson’s disease and epigenetic-based therapies. J. Cell. Physiol. 234, 19307–19319. doi: 10.1002/jcp.28622
Reynolds, G. O., Otto, M. W., Ellis, T. D., and Cronin-Golomb, A. (2016). The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease. Mov. Disord. 31, 23–38. doi: 10.1002/mds.26484
Ruiz-González, D., Hernández-Martínez, A., Valenzuela, P. L., Morales, J. S., and Soriano-Maldonado, A. (2021). Effects of physical exercise on plasma brain-derived neurotrophic factor in neurodegenerative disorders: a systematic review and meta-analysis of randomized controlled trials. Neurosci. Biobehav. Rev. 128, 394–405. doi: 10.1016/j.neubiorev.2021.05.025
Russillo, M. C., Andreozzi, V., Erro, R., Picillo, M., Amboni, M., Cuoco, S., et al. (2022). Sex differences in Parkinson’s disease: from bench to bedside. Brain Sci. 12:12. doi: 10.3390/brainsci12070917
Saade, M., Araujo de Souza, G., Scavone, C., and Kinoshita, P. F. (2021). The role of GPNMB in inflammation. Front. Immunol. 12:674739. doi: 10.3389/fimmu.2021.674739
Salameh, Y., Bejaoui, Y., and El Hajj, N. (2020). DNA methylation biomarkers in aging and age-related diseases. Front. Genet. 11:171. doi: 10.3389/fgene.2020.00171
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., et al. (2018). Effect of high-intensity treadmill exercise on motor symptoms in patients with De novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 75, 219–226. doi: 10.1001/jamaneurol.2017.3517
Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., et al. (2007). Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG Island promoters. PLoS Genet. 3:e181. doi: 10.1371/journal.pgen.0030181
Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., and Pottegård, A. (2021). Association of Glycolysis-Enhancing α-1 blockers with risk of developing Parkinson disease. JAMA Neurol. 78, 407–413. doi: 10.1001/jamaneurol.2020.5157
Simmering, J. E., Welsh, M. J., Schultz, J., and Narayanan, N. S. (2022). Use of glycolysis-enhancing drugs and risk of Parkinson’s disease. Mov. Disord. 37, 2210–2216. doi: 10.1002/mds.29184
Sirugo, G., Williams, S. M., and Tishkoff, S. A. (2019). The missing diversity in human genetic studies. Cells 177, 26–31. doi: 10.1016/j.cell.2019.02.048
Soligard, T., Steffen, K., Palmer, D., Alonso, J. M., Bahr, R., Lopes, A. D., et al. (2017). Sports injury and illness incidence in the Rio de Janeiro 2016 Olympic summer games: a prospective study of 11274 athletes from 207 countries. Br. J. Sports Med. 51, 1265–1271. doi: 10.1136/bjsports-2017-097956
Su, X., Chu, Y., Kordower, J. H., Li, B., Cao, H., Huang, L., et al. (2015). PGC−1α promoter methylation in Parkinson’s disease. PLoS One 10:e0134087. doi: 10.1371/journal.pone.0134087
Suda, M., Shimizu, I., Katsuumi, G., Hsiao, C. L., Yoshida, Y., Matsumoto, N., et al. (2022). Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci. Rep. 12:6522. doi: 10.1038/s41598-022-10522-3
Sujkowski, A., Hong, L., Wessells, R. J., and Todi, S. V. (2022). The protective role of exercise against age-related neurodegeneration. Ageing Res. Rev. 74:101543. doi: 10.1016/j.arr.2021.101543
Tanaka, H., Shimazawa, M., Kimura, M., Takata, M., Tsuruma, K., Yamada, M., et al. (2012). The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci. Rep. 2:573. doi: 10.1038/srep00573
Tsui, K. H., Chang, Y. L., Feng, T. H., Chang, P. L., and Juang, H. H. (2012). Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate 72, 1431–1442. doi: 10.1002/pros.22494
Tsukita, K., Sakamaki-Tsukita, H., and Takahashi, R. (2022). Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease. Neurology 98, e859–e871. doi: 10.1212/WNL.0000000000013218
van der Kolk, N. M., de Vries, N. M., Kessels, R. P. C., Joosten, H., Zwinderman, A. H., Post, B., et al. (2019). Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol. 18, 998–1008. doi: 10.1016/S1474-4422(19)30285-6
Wei, C.-Y., Yang, J.-H., Yeh, E.-C., Tsai, M.-F., Kao, H.-J., Lo, C.-Z., et al. (2021). Genetic profiles of 103,106 individuals in the Taiwan biobank provide insights into the health and history of Han Chinese. NPJ Genom. Med. 6. doi: 10.1038/s41525-021-00178-9
Wu, Y., Goodrich, J. M., Dolinoy, D. C., Sánchez, B. N., Ruiz-Narváez, E. A., Banker, M., et al. (2020). Accelerometer-measured physical activity, reproductive hormones, and DNA methylation. Med. Sci. Sports Exerc. 52, 598–607. doi: 10.1249/MSS.0000000000002175
Xie, R., Okita, Y., Ichikawa, Y., Fikry, M. A., Huynh Dam, K. T., Tran, S. T. P., et al. (2019). Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential. Cancer Sci. 110, 2237–2246. doi: 10.1111/cas.14076
Xu, M., Zhu, J., Liu, X. D., Luo, M. Y., and Xu, N. J. (2021). Roles of physical exercise in neurodegeneration: reversal of epigenetic clock. Transl. Neurodegener. 10:30. doi: 10.1186/s40035-021-00254-1
Zhang, Y.-x., Qin, C.-p., Zhang, X.-q., Wang, Q.-r., Zhao, C.-b., Yuan, Y.-q., et al. (2017). Knocking down glycoprotein nonmetastatic melanoma protein B suppresses the proliferation, migration, and invasion in bladder cancer cells. Tumor Biol. 39:1010428317699119.
Zhou, G., Liu, H., He, M., Yue, M., Gong, P., Wu, F., et al. (2018). Smoking, leisure-time exercise and frequency of self-reported common cold among the general population in northeastern China: a cross-sectional study. BMC Public Health 18:294. doi: 10.1186/s12889-018-5203-5
Keywords: Parkinson’s disease, DNA methylation, epigenesis, genetic, exercise, sex, gender
Citation: Chen Y-C, Liaw Y-C, Nfor ON, Hsiao C-H, Zhong J-H, Wu S-L and Liaw Y-P (2023) Epigenetic regulation of Parkinson’s disease risk variant GPNMB cg17274742 methylation by sex and exercise from Taiwan Biobank. Front. Aging Neurosci. 15:1235840. doi: 10.3389/fnagi.2023.1235840
Edited by:
Shouneng Peng, Icahn School of Medicine at Mount Sinai, United StatesReviewed by:
Gen Li, Fudan University, ChinaKatherine Athayde Teixeira De Carvalho, Pelé Pequeno Príncipe Research Institute, Brazil
Copyright © 2023 Chen, Liaw, Nfor, Hsiao, Zhong, Wu and Liaw. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shey-Lin Wu, MTQxMzJAY2NoLm9yZy50dw==; Yung-Po Liaw, bGlhd3lwQGNzbXUuZWR1LnR3